163 related articles for article (PubMed ID: 34854250)
1. A functional methylation signature to predict the prognosis of Chinese lung adenocarcinoma based on TCGA.
Wang K; Liu Y; Lu G; Xiao J; Huang J; Lei L; Peng J; Li Y; Wei S
Cancer Med; 2022 Jan; 11(1):281-294. PubMed ID: 34854250
[TBL] [Abstract][Full Text] [Related]
2. Screening of Methylation Gene Sites as Prognostic Signature in Lung Adenocarcinoma.
Dong M; Yang Z; Li X; Zhang Z; Yin A
Yonsei Med J; 2020 Dec; 61(12):1013-1023. PubMed ID: 33251775
[TBL] [Abstract][Full Text] [Related]
3. Molecular subtypes based on DNA promoter methylation predict prognosis in lung adenocarcinoma patients.
Shi S; Xu M; Xi Y
Aging (Albany NY); 2020 Nov; 12(23):23917-23930. PubMed ID: 33237038
[TBL] [Abstract][Full Text] [Related]
4. Elevated PHD2 expression might serve as a valuable biomarker of poor prognosis in lung adenocarcinoma, but no lung squamous cell carcinoma.
Xu XL; Gong Y; Zhao DP
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8731-8739. PubMed ID: 30575913
[TBL] [Abstract][Full Text] [Related]
5. Identification of a novel prognostic DNA methylation signature for lung adenocarcinoma based on consensus clustering method.
Cai Q; He B; Xie H; Zhang P; Peng X; Zhang Y; Zhao Z; Wang X
Cancer Med; 2020 Oct; 9(20):7488-7502. PubMed ID: 32860318
[TBL] [Abstract][Full Text] [Related]
6. Genome-wide analysis of methylation CpG sites in gene promoters identified four pairs of CpGs-mRNAs associated with lung adenocarcinoma prognosis.
Pan X; Ji P; Deng X; Chen L; Wang W; Li Z
Gene; 2022 Feb; 810():146054. PubMed ID: 34737001
[TBL] [Abstract][Full Text] [Related]
7. Aberrant OCIAD2 demethylation in lung adenocarcinoma is associated with outcome.
Maki M; JeongMin H; Nakagawa T; Kawai H; Sakamoto N; Sato Y; Noguchi M
Pathol Int; 2022 Oct; 72(10):496-505. PubMed ID: 35920378
[TBL] [Abstract][Full Text] [Related]
8. A methylation-based nomogram for predicting survival in patients with lung adenocarcinoma.
Wang X; Zhou B; Xia Y; Zuo J; Liu Y; Bi X; Luo X; Zhang C
BMC Cancer; 2021 Jul; 21(1):801. PubMed ID: 34247575
[TBL] [Abstract][Full Text] [Related]
9.
Zhang W; Li T; Hu B; Li H
Technol Cancer Res Treat; 2020; 19():1533033820957030. PubMed ID: 33084541
[TBL] [Abstract][Full Text] [Related]
10. Individualized analysis reveals CpG sites with methylation aberrations in almost all lung adenocarcinoma tissues.
Yan H; Guan Q; He J; Lin Y; Zhang J; Li H; Liu H; Gu Y; Guo Z; He F
J Transl Med; 2017 Feb; 15(1):26. PubMed ID: 28178989
[TBL] [Abstract][Full Text] [Related]
11. Aberrant CpG-methylation affects genes expression predicting survival in lung adenocarcinoma.
He W; Ju D; Jie Z; Zhang A; Xing X; Yang Q
Cancer Med; 2018 Nov; 7(11):5716-5726. PubMed ID: 30353687
[TBL] [Abstract][Full Text] [Related]
12. Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma.
Wu P; Zheng Y; Wang Y; Wang Y; Liang N
J Transl Med; 2020 Oct; 18(1):380. PubMed ID: 33028329
[TBL] [Abstract][Full Text] [Related]
13. Identification of a methylomics-associated nomogram for predicting overall survival of stage I-II lung adenocarcinoma.
Wang H; Wei C; Pan P; Yuan F; Cheng J
Sci Rep; 2021 May; 11(1):9938. PubMed ID: 33976305
[TBL] [Abstract][Full Text] [Related]
14. Identification of a DNA-methylome-based signature for prognosis prediction in driver gene-negative lung adenocarcinoma.
Shu M; Huang L; Chen Y; Wang Y; Xie Z; Li S; Zhou J; Wei L; Fu T; Liu B; Chen H; Tang K; Ke Z
Cancer Lett; 2024 Jul; 593():216835. PubMed ID: 38548216
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation.
Zheng Q; Wang Z; Zhang M; Yu Y; Chen R; Lu T; Liu L; Ma J; Liu T; Zheng H; Li H; Li J
BMC Cancer; 2021 Nov; 21(1):1216. PubMed ID: 34774014
[TBL] [Abstract][Full Text] [Related]
16. DNA methylation mediated silencing of microRNA-145 is a potential prognostic marker in patients with lung adenocarcinoma.
Xia W; Chen Q; Wang J; Mao Q; Dong G; Shi R; Zheng Y; Xu L; Jiang F
Sci Rep; 2015 Nov; 5():16901. PubMed ID: 26582602
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive Analysis of DNA Methylation and Gene Expression Datasets Identified MMP9 and TWIST1 as Important Pathogenic Genes of Lung Adenocarcinoma.
Tian W; Li YS; Zhang JH; Li JJ; Gao JH
DNA Cell Biol; 2018 Apr; 37(4):336-346. PubMed ID: 29443542
[TBL] [Abstract][Full Text] [Related]
18. Development and validation of 3-CpG methylation prognostic signature based on different survival indicators for colorectal cancer.
Huang H; Zhang L; Fu J; Tian T; Liu X; Liu Y; Sun H; Li D; Zhu L; Xu J; Zheng T; Jia C; Zhao Y
Mol Carcinog; 2021 Jun; 60(6):403-412. PubMed ID: 33826760
[TBL] [Abstract][Full Text] [Related]
19. Increased S100A15 expression and decreased DNA methylation of its gene promoter are involved in high metastasis potential and poor outcome of lung adenocarcinoma.
Chen YC; Lin MC; Hsiao CC; Zheng YX; Chen KD; Sung MT; Chen CJ; Wang TY; Lin YY; Chang HC; Chen YM; Chang JC
Oncotarget; 2017 Jul; 8(28):45710-45724. PubMed ID: 28498804
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of promoter CpG island hypermethylation and repetitive DNA hypomethylation in stage I lung adenocarcinoma.
Rhee YY; Lee TH; Song YS; Wen X; Kim H; Jheon S; Lee CT; Kim J; Cho NY; Chung JH; Kang GH
Virchows Arch; 2015 Jun; 466(6):675-83. PubMed ID: 25772390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
